Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzomib or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010Revenue: Revenue from collaboration agreement

$  75,041$63,696$ 
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
(Date:11/24/2014)... Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate overview and update at the Piper Jaffray 26 ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at ... . A live audio webcast of the ... Arena,s website at www.arenapharm.com . A replay of the ...
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3
... Alcona Health Center is one of the first organizations ... payment after successfully meeting the requirements for Year One ... Alcona Health received a first-year incentive payment for each ... Medicare and Medicaid Services, resulting in one of the ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that Jeffrey H. Burbank, Chief Executive Officer, will present ... September 20th, at 3:00 p.m. ET.   A webcast ... http://www.nxstage.com/ir.cfm at the time of the presentation. ...
Cached Medicine Technology:SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 2SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 3SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 4
(Date:11/24/2014)... York, NY (PRWEB) November 24, 2014 From ... the progressive world of fitness technology will take center stage ... in Digital Times at the 2015 International CES® ... in the Venetian, Level 2, Bellini 2004). The bond between ... evolves into being less about devices and more about the ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Volpara ... version 1.2 at the 100th Annual Meeting of ... 30-December 5, 2014 (RSNA Booth 1752 – South ... of VolparaAnalytics and the rest of its innovative ... and VolparaDoseRT, which enable personalized measurements of volumetric ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... Mental health issues affect tens ... up families, ruin careers, and generally destroy lives. ... that suffer,” says Hardy Nutritionals® founder ... our specialized nutritional treatments can reverse these disorders ... Over Matter”, the premiere episode of O2 Media’s ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Gersowitz Libo & ... it has received national Tier recognition in the 2015 Edition ... a tiered ranking signals a unique combination of quality law ... proud to receive this honor and especially grateful to our ... important honor and ranking possible,” said Jeff S. Korek, senior ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... Satisfaction and Other ... Areas, ... first Hospital Consumer Assessment of Healthcare Providers and,Systems (HCAHPS) scores for hospitals ... for Special Surgery,(HSS) in New York City scored well above the national ...
... progestin effectively suppressed sperm production , , FRIDAY, March ... and progestin suppresses sperm production faster and more ... by an international team of researchers. , The ... safe, effective and reversible form of male birth ...
... stem cells to be engineered into new blood vessels or ... the hair on their patients heads, according to new research ... , Engineering blood vessels for bypass surgery, promoting the ... using stem cells obtained from the most accessible source -- ...
... Caregivers at Catholic Facilities Join Union, LOS ... an overwhelming majority of healthcare workers at St. ... Medical Foundation health clinics in,the Sacramento area voted ... Workers-West (UHW)., "This victory shows we,re united," ...
... However, patients stay on the new medications longer, study ... so-called second-generation antipsychotics are no better than the older ... a new study finds. , However, it appears that ... likely to continue using them than haloperidol, the study ...
Cached Medicine News:Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3Health News:Hormone Combo May Provide Reversible Male Birth Control Tool 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2Health News:Healthcare Workers Across California Vote to Join UHW 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... offers a complete line of flowmeters, ... CO 2 . They are all ... to best suit your application. With ... to the gas in use, the ...
Medicine Products: